M&A / Deals Eli Lilly to buy trio of vaccine developers in $3.8bn outlay Pharmaceutical TechnologyVia the deals, Lilly is buying biotechs with lead programmes in preventing shingles, bacteria, and Epstein-Barr Virus.Infectious DiseaseRead full story pharminent May 26, 2026 (Last updated: May 26, 2026) Pharmaceutical Technology Via the deals, Lilly is buying biotechs with lead programmes in preventing shingles, bacteria, and Epstein-Barr Virus. Infectious Disease Read full story Post navigation Previous: Arthrosi drug trial in gout delivers for new owner SobiNext: Early data for heart drug affirm Lilly’s billion-dollar bet on Verve Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026